CymitQuimica logo
Receptor de Trk

Receptor de Trk

Los inhibidores de los receptores Trk se dirigen a las quinasa de receptor de tropomiosina (Trk), una familia de tirosina quinasas receptoras que desempeñan un papel significativo en el desarrollo y la función del sistema nervioso. Los receptores Trk están involucrados en la señalización de neurotrofinas, esencial para la supervivencia, diferenciación y crecimiento de las neuronas. La desregulación de la señalización de Trk está asociada con trastornos neurológicos y ciertos tipos de cáncer. En CymitQuimica, ofrecemos inhibidores de receptores Trk para apoyar su investigación en neurobiología, oncología y enfermedades neurodegenerativas.

Se han encontrado 59 productos de "Receptor de Trk"

Ordenar por

Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
productos por página.
  • CG 428

    CAS:
    <p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>
    Fórmula:C43H43FN10O6
    Pureza:99.83%
    Forma y color:Solid
    Peso molecular:814.86
  • Type II TRK inhibitor 1

    CAS:
    <p>Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.</p>
    Fórmula:C35H33F3N8O3
    Pureza:98%
    Forma y color:Solid
    Peso molecular:670.68
  • ENT-C225

    CAS:
    <p>ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.</p>
    Fórmula:C26H40N4O5
    Pureza:99.36% - 99.36%
    Forma y color:Solid
    Peso molecular:488.62
  • PF-06733804

    CAS:
    <p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>
    Fórmula:C20H19F5N4O4
    Pureza:98%
    Forma y color:Solid
    Peso molecular:474.38
  • TRK-IN-24

    CAS:
    <p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>
    Fórmula:C39H45N7O3
    Pureza:98%
    Forma y color:Solid
    Peso molecular:659.82
  • AZ-23

    CAS:
    <p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>
    Fórmula:C17H19ClFN7O
    Pureza:99.4%
    Forma y color:Solid
    Peso molecular:391.83
  • TRK-IN-28

    CAS:
    <p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>
    Fórmula:C27H25F2N7
    Forma y color:Solid
    Peso molecular:485.53
  • TRK-IN-26

    CAS:
    <p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>
    Fórmula:C30H22F2N6O4
    Forma y color:Solid
    Peso molecular:568.53
  • TrkA-IN-7

    CAS:
    <p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>
    Fórmula:C16H13N3O3
    Forma y color:Solid
    Peso molecular:295.293
  • TrkA-IN-8

    CAS:
    <p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>
    Fórmula:C20H16N4
    Forma y color:Solid
    Peso molecular:312.368
  • TrkA-IN-9

    CAS:
    <p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>
    Fórmula:C31H32N4O4
    Forma y color:Solid
    Peso molecular:524.61
  • PF-06273340

    CAS:
    <p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>
    Fórmula:C23H22ClN7O3
    Pureza:98% - 98.00%
    Forma y color:Solid
    Peso molecular:479.92
  • NMS-P626

    CAS:
    <p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>
    Fórmula:C28H35F2N7O4S
    Forma y color:Solid
    Peso molecular:603.68
  • BNN-20

    CAS:
    <p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>
    Fórmula:C20H30O2
    Forma y color:Solid
    Peso molecular:302.45
  • TrkC-IN-1

    CAS:
    <p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>
    Fórmula:C28H20BrN5O2
    Forma y color:Solid
    Peso molecular:538.395
  • ONO-7579

    CAS:
    <p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>
    Fórmula:C24H18ClF3N6O4S
    Forma y color:Solid
    Peso molecular:578.95
  • HS-345

    CAS:
    <p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>
    Fórmula:C19H18N6O2S
    Forma y color:Solid
    Peso molecular:394.45
  • Trk-IN-4

    CAS:
    <p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>
    Fórmula:C24H23F4N5O4
    Pureza:98.13%
    Forma y color:Solid
    Peso molecular:521.46

    Ref: TM-T17169

    1mg
    Descatalogado
    2mg
    Descatalogado
    Producto descatalogado
  • TrkB-IN-1

    CAS:
    <p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>
    Fórmula:C19H16N2O6
    Pureza:98%
    Forma y color:Solid
    Peso molecular:368.34

    Ref: TM-T79011

    ne
    Descatalogado
    5mg
    Descatalogado
    50mg
    Descatalogado
    Producto descatalogado